MCID: HYP159
MIFTS: 11

Hyperinsulinism, Focal

Categories: Rare diseases

Aliases & Classifications for Hyperinsulinism, Focal

MalaCards integrated aliases for Hyperinsulinism, Focal:

Name: Hyperinsulinism, Focal 50

Classifications:



Summaries for Hyperinsulinism, Focal

MalaCards based summary : Hyperinsulinism, Focal is related to hyperinsulinism. The drugs Saxagliptin and Acetylcysteine have been mentioned in the context of this disorder. Affiliated tissues include heart, liver and colon.

Related Diseases for Hyperinsulinism, Focal

Diseases related to Hyperinsulinism, Focal via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 hyperinsulinism 9.7

Symptoms & Phenotypes for Hyperinsulinism, Focal

Drugs & Therapeutics for Hyperinsulinism, Focal

Drugs for Hyperinsulinism, Focal (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 98)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Saxagliptin Approved Phase 4 361442-04-8 11243969
2
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
3
Heparin Approved, Investigational Phase 4 9005-49-6 772 46507594
4
Zinc Approved Phase 4,Phase 3 7440-66-6 32051 23994
5 Mirabegron Approved Phase 4 223673-61-8
6 Hypoglycemic Agents Phase 4,Phase 3,Phase 2,Phase 1
7 insulin Phase 4,Phase 3,Phase 2,Phase 1
8 Insulin, Globin Zinc Phase 4,Phase 3,Phase 2,Phase 1
9 Dipeptidyl-Peptidase IV Inhibitors Phase 4
10 HIV Protease Inhibitors Phase 4,Early Phase 1
11 Hormone Antagonists Phase 4
12 Hormones Phase 4
13 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
14 Incretins Phase 4
15
protease inhibitors Phase 4,Early Phase 1
16 Anticoagulants Phase 4
17 Antidotes Phase 4
18 Anti-Infective Agents Phase 4
19 Antioxidants Phase 4
20 Antiviral Agents Phase 4
21 calcium heparin Phase 4
22 Calcium, Dietary Phase 4
23 Expectorants Phase 4
24 Fat Emulsions, Intravenous Phase 4
25 Fibrinolytic Agents Phase 4
26 N-monoacetylcystine Phase 4
27 Parenteral Nutrition Solutions Phase 4
28 Pharmaceutical Solutions Phase 4
29 Protective Agents Phase 4
30 Respiratory System Agents Phase 4
31 Soybean oil, phospholipid emulsion Phase 4
32 Neurotransmitter Agents Phase 4,Phase 2,Phase 1
33 Adrenergic Agents Phase 4
34 Adrenergic Agonists Phase 4
35 Adrenergic beta-3 Receptor Agonists Phase 4
36 Adrenergic beta-Agonists Phase 4
37 Soy Bean Nutraceutical Phase 4
38
Insulin Glargine Approved Phase 3 160337-95-1
39
Menthol Approved Phase 3 2216-51-5 16666
40
Blueberry Approved, Nutraceutical Phase 2, Phase 3
41 Grape Approved, Nutraceutical Phase 2, Phase 3
42 Glucagon-Like Peptide 1 Phase 3
43 Anthocyanidin Nutraceutical Phase 2, Phase 3
44
Dopamine Approved Phase 2,Phase 1 51-61-6, 62-31-7 681
45
Diazoxide Approved Phase 2 364-98-7 3019
46
Octreotide Approved, Investigational Phase 2 83150-76-9 383414 6400441
47
Pancrelipase Approved Phase 2 53608-75-6
48 Antipsychotic Agents Phase 2
49 Liver Extracts Phase 1, Phase 2
50 Dihydroxyphenylalanine Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 72)

id Name Status NCT ID Phase Drugs
1 Saxagliptin and Atherosclerosis Completed NCT01552018 Phase 4 Saxagliptin;Placebo
2 Mechanism of Fatty Acid-Induced Impairment of Glucose-Stimulated Insulin Secretion Completed NCT00188773 Phase 4 N-acetylcysteine, intralipid, heparin
3 Weight Loss Improves Renal Hemodynamics Completed NCT01356394 Phase 4
4 Mirabegron and Brown Adipose Tissue Recruiting NCT03012113 Phase 4 Mirabegron;Placebo Oral Capsule
5 Feasibility of Once/Daily Administered GLP/1 Receptoragonist (Lixisenatide) in Combination With Basal Insulin Completed NCT02168491 Phase 3 Lixisenatide;Insulin glargine
6 The Improvements of Dietary Supplement of Black Rice on Metabolic Syndrome Completed NCT02407522 Phase 2, Phase 3
7 Dietary Modulation of Gene Expression and Metabolic Pathways in Glucose Metabolism Completed NCT00573781 Phase 2
8 Reducing Weight and Diabetes Risk in an Underserved Population (STRIDE) Completed NCT00790517 Phase 2
9 Partnership Programs to Reduce Cardiovascular Disparities- Morehouse- Emory Partnership Completed NCT00336869 Phase 2
10 Mood and Insulin Resistance in Adolescents At-Risk for Diabetes Completed NCT01425905 Phase 2
11 Transplantation of Microbes for Treatment of Metabolic Syndrome & NAFLD Recruiting NCT02496390 Phase 1, Phase 2
12 Phase II Safety and Efficacy Study of F-DOPA PET/CT in Children With Hyperinsulinemic Hypoglycemia Active, not recruiting NCT01468454 Phase 2 18 F-DOPA
13 Utility of [F-18] fluoroDOPA for Neonatal Hyperinsulinism Active, not recruiting NCT00674440 Phase 2 F-DOPA
14 A Study in Type 2 Diabetic Patients With Repeated Doses of E1 in Combination With G1 Completed NCT00239187 Phase 1 E1 and G1
15 Fluorodopa F 18 in Congenital Hyperinsulinism Recruiting NCT02021604 Phase 1 Fluorodopa F 18
16 Mechanisms of Cerebrovascular Control Recruiting NCT02936687 Phase 1 NOS Inhibition;ET-1 Inhibition;Placebo
17 Long Term Glucose Metabolism in Conservatively Treated Patients With Congenital Hyperinsulinism Unknown status NCT01819584
18 Effects of Dietary Fiber on Insulin Sensitivity Unknown status NCT01521806
19 The Odense Overweight Intervention Study Unknown status NCT01574352
20 Meta-analysis of Fructose-Containing Sugar Sweetened Beverages (SSBs) and Weight Change Unknown status NCT01608607
21 Cardiovascular Risk Factors After Renal Transplantation in Children and Adults Unknown status NCT01008306
22 Feasibility Study - Integrated Sensor and Infusion Set. Trial III Completed NCT01773668
23 Walking and Dietary Modification for Recurrent Early Miscarriages Completed NCT03023137
24 Role of Colonic Events on Metabolism and Appetite Control: A Synbiotic Approach Completed NCT01718418 Early Phase 1
25 Effects of Dietary Fibre on Glucose Metabolism and Satiety Completed NCT02093481 Early Phase 1
26 Over-night Effect of Dietary Fiber on Glucose Metabolism and Satiety Completed NCT02347293 Early Phase 1
27 A Family Based Intervention to Reduce the Risk of Type 2 Diabetes in Children Completed NCT01146314
28 Fat Metabolism in Pregnancy and Neonatal Heart Function in Diabetes Completed NCT01346527
29 A Simple Dietary Message to Improve Dietary Quality for Metabolic Syndrome Completed NCT00911885
30 Environmental Triggers Of Cardiometabolic Disease Completed NCT01548300
31 Pharmacist - Physician Collaborative Approach to the Management of Metabolic Syndrome Completed NCT01099306
32 Carnitine Infusion and Insulin Resistance Completed NCT02722902 Carnitor
33 Resistant Starch Insulin Sensitivity Trial Completed NCT01027325
34 Magnesium and Vascular Stiffness Completed NCT02235805
35 "Can Soluble-CD163 Discriminate Between Healthy and Unhealthy Obese Individuals?" Completed NCT01463449
36 Bioactive Plant Foods: Effects on Functional Bioavailability and Genomic Stability Completed NCT00963118
37 Lifestyle Intervention for Pakistani Women in Oslo Completed NCT00425269
38 Body Weight and Vascular Function Completed NCT01675401
39 SIT LESS 3: The Effect of Low Intensity Physical Activity on Insulin Sensitivity, Mood and Cognitive Performance Completed NCT02394249
40 Exercise-Induced Epigenetic Modifications in Obese Aging Women Completed NCT01977885
41 The Flamenco (Fitness League Against MENopause COsts) Project Completed NCT02358109
42 Diet and Well-being of Young Danish Children Completed NCT02170428
43 Cardiovascular Diseases in HIV-infected Patients HIV-HEART Study: 7.5 Years Follow-up Completed NCT01667068
44 Metabolic Syndrome and Gen-polymorphs Influence on Weightloss Among Children in Treatment for Overweight Completed NCT00823277
45 Latinos Combating Diabetes Completed NCT01831921
46 Exercise Capacity and Dyspnea in Obese Patients With Metabolic Syndrome: Effects of Weight Loss Completed NCT03035149
47 Cardiovascular Diseases in HIV-infected Patients HIV-HEART Study: 5 Years Follow-up Completed NCT01196273
48 Bariatric Surgery And Adipose Inflammation Dysfunction and Type 2 Diabetes Mellitus Recruiting NCT01882036
49 Genetic Studies of Insulin and Diabetes Recruiting NCT00001987
50 Glucose Monitoring During Threatening Preterm Birth in Patients With and Without Gestational Diabetes Mellitus Recruiting NCT03007186

Search NIH Clinical Center for Hyperinsulinism, Focal

Genetic Tests for Hyperinsulinism, Focal

Anatomical Context for Hyperinsulinism, Focal

MalaCards organs/tissues related to Hyperinsulinism, Focal:

39
Heart, Liver, Colon

Publications for Hyperinsulinism, Focal

Variations for Hyperinsulinism, Focal

Expression for Hyperinsulinism, Focal

Search GEO for disease gene expression data for Hyperinsulinism, Focal.

Pathways for Hyperinsulinism, Focal

GO Terms for Hyperinsulinism, Focal

Sources for Hyperinsulinism, Focal

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....